Rentschler Biopharma vs Samsung Biologics: CDMO Comparison
Side-by-side comparison of Rentschler Biopharma and Samsung Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Rentschler Biopharma has FDA inspections on record (1); Samsung Biologics does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Rentschler Biopharma holds 2 active EMA GMP certificates; Samsung Biologics does not appear in EudraGMDP.
- Composite Signal Score: Rentschler Biopharma 80/100 vs Samsung Biologics 68/100 — a 11-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Rentschler Biopharma and Samsung Biologics qualify as Recombinant Proteins manufacturers; Rentschler Biopharma carries the higher composite Signal Score for Recombinant Proteins programs in this comparison.
What to evaluate for Recombinant Proteins programs
Both Rentschler Biopharma and Samsung Biologics qualify as Recombinant Proteins CDMOs. When choosing between them for Recombinant Proteins programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
Frequently asked: Rentschler Biopharma vs Samsung Biologics
Which has the stronger FDA inspection record, Rentschler Biopharma or Samsung Biologics?
Both Rentschler Biopharma and Samsung Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Rentschler Biopharma has 1 FDA inspection on record; Samsung Biologics has 0.
How do Rentschler Biopharma and Samsung Biologics compare on European GMP coverage?
Rentschler Biopharma holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Samsung Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Recombinant Proteins manufacturing — Rentschler Biopharma or Samsung Biologics?
Both Rentschler Biopharma and Samsung Biologics are tagged as Recombinant Proteins CDMOs in our directory, so both are credible options for Recombinant Proteins programs. The most important differentiator for Recombinant Proteins selection is typically expression host & scale: Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Rentschler Biopharma carries a Signal Score of 80/100 and Samsung Biologics carries 68/100 — a meaningful lead for Rentschler Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →